Observations placeholder
Pentacarinat and Pentamidine
Identifier
019836
Type of Spiritual Experience
Background
A description of the experience
Pentamidine (formulated as a salt, pentamidine diisethionate or dimesilate) is an antimicrobial medication given for prevention and treatment of Pneumocystis pneumonia (PCP) caused by Pneumocystis jirovecii (formerly known as Pneumocystis carinii), a severe interstitial type of pneumonia often seen in patients with HIV infection. The drug is also the mainstay of treatment for stage I infection with Trypanosoma brucei gambiense (West African Trypanosomiasis).
Pentamidine can cause allergic and toxic side effects, most commonly having effects on the pancreas, which in part depend on the daily and/or cumulative dose:
- Blood: Pentamidine frequently causes leukopenia and less often thrombopenia, which may cause symptomatic bleeding. Some cases of anemia, possibly related to folic acid deficiency, have been described.
- Cardiovascular: Hypotension, which may be severe. Severe or fatal arrhythmias and heart failure are quite frequent[citation needed]
- Gastrointestinal: Nausea, vomiting, gastrointestinal discomfort, diarrhea, unpleasant taste
- Kidney: 25 percent develop signs of nephrotoxicity ranging from mild, asymptomatic azotemia (increased serum creatinine and urea) to irreversible renal failure. Ample fluids or intravenous hydration may prevent some nephrotoxicity.
- Liver: Elevated liver enzymes are associated with intravenous use of pentamidine. Hepatomegaly and hepatitis have been encountered with long term prophylactic use of pentamidine inhalation.
- Neurological: Dizziness, drowsiness, neuralgia, confusion, hallucinations, seizures and other central side effects are reported.
- Pancreas: Hypoglycemia that requires symptomatic treatment is frequently seen. On the other hand, pentamidine may cause or worsen diabetes mellitus
- Respiratory: Cough and bronchospasm, most frequently seen with inhalation.
- Skin: Severe local reactions after extravasculation of intravenous solutions or following intramuscular injection treatment have been seen. Pentamidine itself may cause rash, or rarely Stevens–Johnson syndrome or Lyell syndrome.
Others
Eye discomfort, conjunctivitis, throat irritation, splenomegaly, Herxheimer reaction, electrolyte imbalances (e.g. hypocalcemia).
On Jan, 28, 2016: 355 people reported to have side effects when taking Pentacarinat. Among them, 3 people (0.85%) have Hallucination.
On Jan, 3, 2016: 1,355 people reported to have side effects when taking Pentamidine isethionate. Among them, 1 people (0.07%) has Hallucination.
On Jan, 28, 2016: 355 people reported to have side effects when taking Pentacarinat. Among them, 2 people (0.56%) have Death.
On Jan, 28, 2016: 1,355 people reported to have side effects when taking Pentamidine isethionate. Among them, 13 people (0.96%) have Death.
Time on Pentamidine isethionate when people have Death :
< 1 month | 1 - 6 months | 6 - 12 months | 1 - 2 years | 2 - 5 years | 5 - 10 years | 10+ years | |
Death | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Gender of people who have Death when taking Pentamidine isethionate :
Female | Male | |
Death | 14.29% | 85.71% |
Age of people who have Death when taking Pentamidine isethionate :
0-1 | 2-9 | 10-19 | 20-29 | 30-39 | 40-49 | 50-59 | 60+ | |
Death | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 28.57% | 42.86% | 28.57% |